|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01952 EVEREST MED
Nominal 
48.250 +0.700 (+1.472%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| ROAA (%) | -19.408% | -13.634% | -3.730% | -14.285% | -117.705% |
| ROAE (%) | -23.036% | -15.899% | -4.283% | -15.844% | -189.237% |
| Return on Capital Employed (%) | -25.001% | -15.512% | -4.305% | -15.822% | -77.613% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Gross Profit Margin (%) | 74.558% | 72.673% | 63.688% | 57.407% | N/A |
| EBITDA Margin (%) | -138.788% | -676.639% | -1855.769% | -1854925.926% | N/A |
| Pre-tax Profit Margin (%) | -147.362% | -670.571% | -1933.044% | -1867998.148% | N/A |
| Net Profit Margin (%) | -147.362% | -670.571% | -1933.107% | -1867998.148% | N/A |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Current Ratio (X) | 2.540 X | 7.628 X | 3.924 X | 9.945 X | 24.056 X |
| Quick Ratio (X) | 2.522 X | 7.570 X | 3.911 X | 9.944 X | 24.056 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Total Liabilities / Total Assets(%) | 17.868% | 13.929% | 14.517% | 11.343% | 8.507% |
| Total Debt / Total Assets (%) | 11.076% | 8.845% | 7.615% | 7.298% | 5.983% |
| Net Debt / Total Assets (%) | -6.760% | -0.215% | 0.195% | -32.427% | -53.948% |
| Total Debt / Shareholders' Funds (%) | 13.486% | 10.277% | 8.908% | 8.232% | 6.539% |
| Long Term Debt / Shareholders' Funds (%) | 2.127% | 9.445% | 1.049% | 7.753% | 6.261% |
| Net Debt / Shareholders' Funds (%) | -8.231% | -0.250% | 0.229% | -36.575% | -58.964% |
| Net Cash / (Debt) ($) | 335.226M | 12.437M | (12.927M) | 2.155B | 4.034B |
| Net Cash / (Debt) per share ($) | 1.027 | 0.038 | (0.041) | 7.219 | 13.757 |
| Total Debt / Capital Employed (%) | 13.186% | 9.380% | 8.768% | 7.608% | 6.136% |
| Interest Coverage Ratio (X) | N/A | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Inventory Turnover (Day) | 33.523 Day | 162.173 Day | 474.775 Day | 7093.696 Day | N/A |
| Receivables Turnover (Day) | 106.769 Day | 79.810 Day | 75.086 Day | 331.204 Day | N/A |
| Payables Turnover (Day) | 24.536 Day | 135.337 Day | 1400.479 Day | 319016.759 Day | N/A |
| Remarks: | Real time quote last updated: 09/05/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -1,041,375,000 |
| %Change | 23.318% |
| EPS / (LPS) | RMB -3.240 |
| NBV Per Share (¥) | RMB 12.474 |